profit from every $100 of sales.
$0$100
MiNK Therapeutics
$10.22+2.14% today
-25.2% in 1 year
1-year low $8.561-year high $14.21
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What MiNK Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$12.5 million of profit last year.
SalesProfit
MiNK Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MiNK Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads MiNK Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -31 | -23 | -11 | -12 | |
| -31 | -23 | -10 | -12 | |
| -28 | -22 | -11 | -12 | |
| -8.30 | -6.54 | -2.86 | -2.93 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 21 | 5 | 6 | 14 |
| Cash | 20 | 3 | 5 | 13 |
| Total debt | – | – | 5 | 5 |
| Total liabilities | 22 | 23 | 25 | 28 |
| -0 | -18 | -20 | -14 | |
| 3 | 3 | 4 | 4 | |
| – | – | – | – | |
| 6,975.1% | 124.4% | 55.1% | 87.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -16 | -10 | -6 | |
| 0 | 0 | – | – | |
| -19 | -16 | -10 | -6 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 3 | 4 | 2 | 3 |
Valuation
- –
- –
- –
- -3.8×
- –
- –
- –
- -11,356.9%
- -23.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -415.5%
- 1,436.8%
- 76.0%
- -120.2%
- -415.5%
- –
Growth
- –
- –
- −61,908.1%
- –
- +6.3%
Financial health
- -0.8×
- 0.00
- 0.0%
- –
- 1.38
- 1.38
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 888
What analysts expect
- Average price target
- $35.00
- Range
- $35.00 – $35.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.57 | -0.77 | +26.0% |
| Mar 17, 2026 | -0.52 | -0.68 | +23.5% |
| Nov 14, 2025 | -0.65 | -0.86 | +24.4% |
| Aug 14, 2025 | -1.06 | -0.55 | −92.7% |
| May 15, 2025 | -0.70 | -0.61 | −14.8% |
| Mar 18, 2025 | -0.62 | -0.50 | −24.0% |
| Nov 14, 2024 | -0.50 | -0.80 | +37.5% |
| Aug 13, 2024 | -0.70 | -1.00 | +30.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
43No pass
Philip Fisher
32No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
39No pass
Terry Smith
39No pass
Questions about MiNK Therapeutics
Is MiNK Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MiNK Therapeutics AI analysis
What does MiNK Therapeutics do?
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is in Biotechnology.
Does MiNK Therapeutics pay a dividend?
No. MiNK Therapeutics does not pay a dividend at the moment.
Is MiNK Therapeutics stock halal?
Yes. MiNK Therapeutics passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
How has MiNK Therapeutics stock done over the past year?
Down 25.2% over the past twelve months, to $10.22. It traded between $8.56 and $14.21 and is 28.1% below its high.
Who are MiNK Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with MiNK Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.